Dendritic cells as cancer therapeutics

Bryant, Christian; Sutherland, Sarah; Kong, Benjamin Y.; Papadimitrious, Michael S.; Fromm, Phillip D.; Hart, Derek N.J.

doi:10.1016/j.semcdb.2018.02.015

Cited by 52 publications

(50 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, cancer immune-therapies have generated intense interest [28]. DCs are an important target for generating specific anti-tumor immunity [29], as they trigger adaptive responses by presenting tumor antigens to T cells. T cells are categorized by cell membrane markers such as CD4 and CD8 [1].…”

Section: Cancer Immunologymentioning

confidence: 99%

An immunological perspective for preventing cancer with berries

Pan

Huang

Oshima³

et al. 2018

JBR

View full text Add to dashboard Cite

Berries and their phytochemicals have well documented chemopreventive roles, but understanding their ability to regulate cancer immunology is only beginning to be explored. The literature, including human studies, suggests that berry components can modulate our immune system to delay cancer development. Moreover, their wide spectrum of phytochemicals suggests that they might influence the functions of multiple immune cells and different aspects of cancer immunity. Cancer immune-therapies are showing promise for some types of cancer because they boost T cells’ ability to recognize tumor cells – an essential prelude to destruction. Recognition occurs after dendritic cells present antigen, such as tumor antigen, to T cells, generating an adaptive response. Therefore, the potential of berries to aid cancer immune-therapies by, for example, regulating dendritic cells, warrants further investigation in animal and human studies. More information is also needed about berries’ effects on the entire spectrum of immunity so that a comprehensive view can inform efforts to use berries to enhance immune responses during cancer prevention and treatment. This review summarizes the effects of berries as anti-tumor agents from the immunological perspective in tumor-bearing animals and humans.

show abstract

Section: Cancer Immunologymentioning

confidence: 99%

An immunological perspective for preventing cancer with berries

Pan

Huang

Oshima³

et al. 2018

JBR

View full text Add to dashboard Cite

show abstract

“…While studies in adult cancers have shown that efficacy of monocyte derived ttRNA DC vaccines might be dose dependent, larger dose vaccines do not necessarily produce proportional T cell responses but might rather dampen them by inducing immune tolerance [56] . In fact, pre-clinical studies have shown that as few as 85 mature DCs can produce adequate T-cell responses and ideally should be less than 5 × 10 6 cells per dose [56,57] . Several routes of administration have been tried including intravenous, intradermal, and intranodal, injections [56] .…”

Section: Dose and Route Of Administration Of Ttrna DC Vaccine And Immmentioning

confidence: 99%

“…In fact, pre-clinical studies have shown that as few as 85 mature DCs can produce adequate T-cell responses and ideally should be less than 5 × 10 6 cells per dose [56,57] . Several routes of administration have been tried including intravenous, intradermal, and intranodal, injections [56] . Most vaccine cells end up in kidneys, lung, and spleen when given intravenously (as assessed by radiolabeling studies) and intranodal administration does not result in major distribution of DCs to other regional lymph nodes [56] .…”

Section: Dose and Route Of Administration Of Ttrna DC Vaccine And Immmentioning

confidence: 99%

Total tumor RNA pulsed dendritic cells plus adoptive transfer of ex-vivo enriched autologous T-lymphocytes in the treatment of children with primary brain tumors

Gururangan¹,

Sayour²,

Mitchell³

2018

View full text Add to dashboard Cite

show abstract

“…Such conditions may coexist with depressive disorders . There is also much interest in the use of immune therapies, such as the potential exploitation of dendritic cells, to treat cancer …”

Section: Introductionmentioning

confidence: 99%

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

et al. 2020

View full text Add to dashboard Cite

Given the critical role that the immune system plays in a multitude of diseases, having a clear understanding of the pharmacology of the immune system is crucial to new drug discovery and development. Here we describe the International Union of Basic and Clinical Pharmacology (IUPHAR) Guide to Immunopharmacology (GtoImmuPdb), which connects expert-curated pharmacology with key immunological concepts and aims to put pharmacological data into the hands of immunologists. In the pursuit of new therapeutics, pharmacological databases are a vital resource to researchers through providing accurate information on the fundamental science underlying drug action. This extension to the existing IUPHAR/British Pharmacological Society Guide to Pharmacology supports research into the development of drugs targeted at modulating immune, inflammatory or infectious components of disease. To provide a deeper context for how the resource can support research we show data in GtoImmuPdb relating to a case study on the targeting of vascular inflammation.

show abstract

Dendritic cells as cancer therapeutics

Cited by 52 publications

References 200 publications

An immunological perspective for preventing cancer with berries

An immunological perspective for preventing cancer with berries

Total tumor RNA pulsed dendritic cells plus adoptive transfer of ex-vivo enriched autologous T-lymphocytes in the treatment of children with primary brain tumors

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

Contact Info

Product

Resources

About